Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study conducted molecular docking and ADME property analysis on 144 newly designed isatin analogs, suggesting they exhibit lead-like properties for targeting EGFR enzymes.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

This Phase II trial found that topical GT20029 significantly increased hair count and width at 12 weeks in Chinese men with androgenetic alopecia compared to placebo, with good tolerability and similar adverse event incidence across groups.

This study found that dutasteride increased hair growth metrics significantly more than finasteride in Korean men with AGA, but a meta-analysis suggests no overall significant efficacy difference between the two drugs.

This article reviews current diagnostic and treatment approaches for androgenetic alopecia but reports no new results, focusing on its progression and medical management options.

This study observed that a combination of sinapic acid and glabridin from Zhimo herbal extract improved hair growth and reduced oxidative stress in a DHT-induced model of androgenetic alopecia in mice by preventing ferroptosis and stabilizing β-Catenin, offering potential application for AGA treatment.

This study found that a heterozygous missense mutation in ATR is associated with a hereditary cancer syndrome, manifested by oropharyngeal cancer and other anomalies, in an autosomal-dominant inheritance pattern across a five-generation family.

This article discusses the potential of combining growth factor therapy with LLLT LED therapy for hair regrowth in androgenetic alopecia, but it does not report new clinical results.

This study found that mouse and human protransglutaminase 3 enzymes require calcium-regulated activation for their role in later stages of cell envelope formation in the epidermis and hair follicle.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

This meta-analysis suggests that the G allele of AR StuI polymorphism might be a potential risk factor for AGA, particularly in white populations.

This study reported that Tianma Gouteng decoction improved hair follicle regeneration in mice and identified its potential mechanism, primarily involving the Wnt/β-catenin signaling pathway, through a combination of network pharmacology, molecular docking, and experimental validation.

This study observed that in human scalp hair follicles, BTNL2 expression is lower in stressed conditions, which correlates with increased cytotoxic activity by gamma/delta and CD8+ T cells, suggesting a possible role for BTNL2 in controlling immune responses relevant to alopecia areata.

This study reports that combination therapies, including surgical and various medical treatments, show promise for managing androgenetic alopecia, though further research is necessary to confirm the safety and effectiveness of emerging therapies.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study found that trans-3,4'-Dimethyl-3-hydroxyflavanone reduces active TGF-beta2 levels in human keratinocytes, suggesting it may enhance hair growth by suppressing the TGF-beta2 activation pathway.

This study found that botulinum toxin type A may reduce apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

This case report illustrates a rare instance of mixed germ cell tumor in the pituitary with hyperandrogenism, emphasizing the importance of thorough examination and hormone evaluation in identifying hormonal dysfunctions.

This study found that A(3)B(5) downregulates melanin production and suppresses melanoma cell growth by promoting proteasomal degradation of TRP-2.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This study found that in male androgenetic alopecia, the contrast enhanced phototrichogram technique was superior in detecting changes in hair density and thickness compared to other methods.

ALDOA levels drop in hair cells during hair loss.

This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.

In this study, compound glycyrrhizin promoted hair regrowth in a testosterone-induced alopecia mouse model and increased human hair dermal papilla cell proliferation, likely through activating the Wnt/β-catenin pathway.

This review provides an overview of androgenetic alopecia, detailing its causes, diagnostic methods, and current treatments, noting that combination therapies show promise but newer options like cell-based treatments require more research.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.